NKTR - Nektar Therapeutics

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
58.41
+0.55 (+0.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close57.86
Open57.38
Bid0.00 x 1800
Ask0.00 x 1200
Day's Range56.57 - 58.81
52 Week Range17.51 - 111.36
Volume2,760,327
Avg. Volume3,778,289
Market Cap10.012B
Beta2.72
PE Ratio (TTM)N/A
EPS (TTM)-0.81
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est101.56
Trade prices are not sourced from all markets
  • ACCESSWIRE17 hours ago

    Today's Research Reports on Trending Tickers: Verastem and Nektar Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 18, 2018 / U.S. market plunged on Friday, but well-off session lows as investors appeared to look at previous signs of escalating trade tension between Washington and Beijing. ...

  • Nektar Therapeutics Closed Higher on June 14
    Market Realist4 days ago

    Nektar Therapeutics Closed Higher on June 14

    The S&P 500’s top gainers on June 14 were: Nektar Therapeutics (NKTR) gained 5.5%. Royal Caribbean Cruises (RCL) gained 5.1%. Comcast Corp A (CMCSA) gained 4.6%. Discovery Comm A (DISCA) gained 4.5%. Incyte (INCY) gained 4.4%. Nektar Therapeutics 

  • PR Newswire5 days ago

    New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting

    SAN FRANCISCO, June 14, 2018 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego, California. "We are privileged that these meaningful new data from our clinical trials, as well as our translational research, were recognized for oral presentation at the prestigious CPDD meeting," said Steve Doberstein, Ph.D., Senior Vice President and Chief Research and Development Officer of Nektar Therapeutics.

  • Barrons.com7 days ago

    Former Incyte CEO Buys Slumping Nektar Shares

    Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...

  • Barrons.com8 days ago

    Biotech, Nektar Therapeutics Can't Handle Mondays

    Nektar Therapeutics (NKTR) went on a rollercoaster ride last week, and is down again today, following a downgrade, along with much of the rest of biotech. First, it notched a painful 40% plunge last Monday, in reaction to a presentation detailing its experimental drug NKTR-214 at a meeting at the American Society of Clinical Oncology, which didn't live up to high expectations.  Then, it bounced back for two days of gains of 6.5% and 7.2% on Tuesday and Wednesday, respectively, before the optimism ran out and it fell more than 11% on Thursday.  All of that movement means that while the intensely volatile shares are up 185% in the past 12 months, they've fallen more than 12% year to date. Today, the shares are down again, after H.C. Wainwright threw in the towel and downgraded Nektar to Neutral with a $54 price target.

  • Benzinga8 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

    The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves . Nektar Therapeutics (NASDAQ: NKTR ) slumped about 42 percent, while Deciphera Pharmaceuticals ...

  • See what the IHS Markit Score report has to say about Nektar Therapeutics.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Nektar Therapeutics.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • S&P 500’s Top Losses: Nektar Therapeutics and Lam Research
    Market Realist11 days ago

    S&P 500’s Top Losses: Nektar Therapeutics and Lam Research

    The S&P 500’s top losses on June 7 were: Nektar Therapeutics (NKTR) declined 11.7%. Seagate Technology (STX) declined 5.9%. Lam Research (LRCX) declined 5.4%. J.M. Smucker (SJM) declined 5.4%. Advanced Micro Devices (AMD) declined 5%. Nektar Therapeutics 

  • Financial Times11 days ago

    [$$] Are you following the wrong small-cap index?

    Small companies are setting a record pace on Wall Street this year, but many investors are missing out on the cream thanks to a divergence between the two main benchmarks that define the sector for fund managers. and have left the S&P 500 well behind in performance terms so far this year: the S&P 500’s 3.6 per cent rise pales when compared with 10.6 per cent for the S&P 600 index and 8.6 per cent for the Russell 2000, the two main indices tracking small-caps. The performance of these benchmarks affirms the over-arching bull case on small-caps generally, but why is the S&P 600 outperforming the Russell 2000?

  • Why Nektar Therapeutics Stock Stumbled 11.8% Today
    Motley Fool11 days ago

    Why Nektar Therapeutics Stock Stumbled 11.8% Today

    Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.

  • Barrons.com11 days ago

    After the Bell: 21 Out of 30 Dow Stocks Can't Be Wrong, Can They?

    The Dow Jones industrial Average gained nearly 100 points even as everything else fell apart. The Nasdaq Composite, which had been rallied for four days, sank 0.7% to 7635.07, while the S&P 500 dipped 0.1% to 2770.37. "The Dow continued higher, but the NASDAQ Composite took a hit," writes Todd Market Forecast's Stephen Todd.

  • Nektar Therapeutics: S&P 500’s Top Gainer
    Market Realist12 days ago

    Nektar Therapeutics: S&P 500’s Top Gainer

    The S&P 500’s top gainers on June 6 were: Nektar Therapeutics (NKTR) gained 7.2%. Equifax (EFX) gained 6.1%. Dish Network (DISH) gained 5.8%. Devon Energy (DVN) gained 5.6%. Adv Micro Devices (AMD) gained 5.5%. Nektar Therapeutics 

  • What You Should Know about Nektar’s Cash Flows and Valuations
    Market Realist12 days ago

    What You Should Know about Nektar’s Cash Flows and Valuations

    Nektar Therapeutics (NKTR) used up $52.5 million on operating activities in Q1 2018 compared with $34.6 million in Q1 2017. Operating cash flow in Q1 2018 included $57.5 million of net operating cash use along with $5 million for interest payments on Nektar’s senior secured notes partially offset by the receipt of a milestone payment of $10 million from Baxalta. Nektar expects cash used in operating activities in fiscal 2018 to increase as compared with fiscal 2017 mainly as a result of higher research and development expenses.

  • Analyzing Nektar Therapeutics’ Operational Performance
    Market Realist12 days ago

    Analyzing Nektar Therapeutics’ Operational Performance

    Nektar Therapeutics’ (NKTR) cost of goods sold increased from $6.1 million in Q1 2017 to $6.6 million in Q1 2018. This increase was due to Nektar’s clinical development of NKTR-214, NKTR-181, and NKTR-262 and preclinical activities for NKTR-255. Nektar Therapeutics expects research and development expenses to increase significantly in fiscal 2018 as compared to fiscal 2017 mainly on account of the development of NKTR-214 under its collaboration agreement with Bristol-Myers Squibb.

  • Barrons.com12 days ago

    After the Bell: Dow Gains 346 Points and Didn't Need Tech to Do It

    The Dow Jones Industrial Average gained more than 300 points today. Today, it was the Dow's turn. The Dow got a huge lift from Boeing (BA), which rose 3.2% to $371.56, and added 78.91 points to the price-weighted benchmark.

  • Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today
    Motley Fool12 days ago

    Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today

    Find out which of these stocks picked up the most ground.

  • Here's Why Nektar Therapeutics Jumped as Much as 17% Today
    Motley Fool12 days ago

    Here's Why Nektar Therapeutics Jumped as Much as 17% Today

    The biopharma stock is bouncing after a wild week.

  • Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap
    Investor's Business Daily12 days ago

    Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap

    Nektar Therapeutics popped for the second day running Wednesday as it tried to recover from a melanoma presentation with Bristol-Myers Squibb.

  • How Was Nektar Therapeutics’ Top-Line Performance?
    Market Realist13 days ago

    How Was Nektar Therapeutics’ Top-Line Performance?

    In the first quarter of 2018, Nektar Therapeutics (NKTR) generated total revenues of $38 million compared with $24.7 million in the first quarter 2017. Nektar’s licensing and collaboration revenues rose more than 100% from $6 million in Q1 2017 to $13.7 million in Q1 2018. This increase was primarily due to the recognition of a milestone payment of $10 million received by Nektar in March 2018 resulting from the marketing authorization of Adynovi in the European Union in January 2018.

  • What’s the Upside Potential of Nektar Therapeutics?
    Market Realist13 days ago

    What’s the Upside Potential of Nektar Therapeutics?

    Nektar Therapeutics (NKTR) is a San-Francisco-headquartered biopharmaceutical company with a focus on research. It is developing drug candidates that make use of Nektar’s advanced polymer conjugate technology platforms. Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating, while one analyst has given it a “hold” rating.

  • What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?
    Market Realist13 days ago

    What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?

    After a stellar rise in the past 12 months, Nektar Therapeutics (NKTR) stock fell more than 40% on June 4, which wiped out close to $6 billion of the company’s market cap. This drop was after Bristol Myers Squibb (BMY) and Nektar reported preliminary results from the currently ongoing phase one and two study for NKTR-214 in combination with Opdivo for treating patients with stage four metastatic melanoma, renal cell carcinoma, and urothelial cancers. The price of Bristol-Myers Squibb stock also witnessed selling pressure and fell almost 3% on June 4.

  • Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5%
    Zacks13 days ago

    Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5%

    Nektar Therapeutics (NKTR) shares rose nearly 7% in the last trading session, amid huge volumes.

  • ASCO Ends: Winners & Losers at the Key Cancer Research Event
    Zacks13 days ago

    ASCO Ends: Winners & Losers at the Key Cancer Research Event

    The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

  • Nektar Therapeutics’ Share Price Fell 41.8% on June 4
    Market Realist13 days ago

    Nektar Therapeutics’ Share Price Fell 41.8% on June 4

    On June 4, Nektar Therapeutics (NKTR) closed at $52.6—almost 41.8% lower than its previous close of $90.35. The company’s market capitalization fell by ~$6.0 billion to ~$9.0 billion.

  • Cramer's lightning round: 'I beg you' to hold the stock of Hasbro
    CNBC13 days ago

    Cramer's lightning round: 'I beg you' to hold the stock of Hasbro

    Jim Cramer rattles off his take on callers' favorite stocks, including a toymaker recovering from Toys R Us' bankruptcy.